{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:26:09Z","timestamp":1764332769668,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T00:00:00Z","timestamp":1561766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T00:00:00Z","timestamp":1561766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11096-019-00873-9","type":"journal-article","created":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T09:02:49Z","timestamp":1561798969000},"page":"1143-1147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Drug safety surveillance within a strategy for the management of non-chemotherapy drug-induced neutropenia"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2071-8928","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Revuelta-Herrero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Garc\u00eda-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Anguita-Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"de Lorenzo-Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Ortega-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Sanjurjo-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,29]]},"reference":[{"issue":"9","key":"873_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","volume":"146","author":"F Andersohn","year":"2007","unstructured":"Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146(9):657\u201365.","journal-title":"Ann Intern Med"},{"issue":"11","key":"873_CR2","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/14740338.2017.1376645","volume":"16","author":"E Andr\u00e8s","year":"2017","unstructured":"Andr\u00e8s E, Mourot-Cottet R. Non-chemotherapy drug-induced neutropenia\u2014an update. Expert Opin Drug Saf. 2017;16(11):1235\u201342.","journal-title":"Expert Opin Drug Saf."},{"issue":"3","key":"873_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJM199307153290303","volume":"329","author":"JM Alvir","year":"1993","unstructured":"Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162\u20137.","journal-title":"N Engl J Med"},{"issue":"7","key":"873_CR4","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/archinte.1992.00400190095018","volume":"152","author":"BL Strom","year":"1992","unstructured":"Strom BL, Carson JL, Schinnar R, et al. Descriptive epidemiology of agranulocytosis. Arch Intern Med. 1992;152(7):1475\u201380.","journal-title":"Arch Intern Med"},{"issue":"1","key":"873_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ajh.20489","volume":"81","author":"DW Kaufman","year":"2006","unstructured":"Kaufman DW, Kelly JP, Issaragrisil S, Laporte J-R, Anderson T, Levy M, et al. Relative incidence of agranulocytosis and aplastic anemia. Am J Hematol. 2006;81(1):65\u20137.","journal-title":"Am J Hematol"},{"issue":"2","key":"873_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1046\/j.1365-2125.2000.00132.x","volume":"49","author":"K Fattinger","year":"2000","unstructured":"Fattinger K, Roos M, Verg\u00e8res P, et al. Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol. 2000;49(2):158\u201367.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"873_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/ajh.21433","volume":"84","author":"D Tesfa","year":"2009","unstructured":"Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol. 2009;84(7):428\u201334.","journal-title":"Am J Hematol"},{"issue":"2","key":"873_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"873_CR9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2125.1996.tb00040.x","volume":"41","author":"WH Inman","year":"1996","unstructured":"Inman WH. Attitudes to adverse drug reaction reporting. Br J Clin Pharmacol. 1996;41(5):434\u20135.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"873_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"issue":"6","key":"873_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/bcpt.12418","volume":"117","author":"N Medrano-Casique","year":"2015","unstructured":"Medrano-Casique N, Tong HY, Borobia AM, et al. Non-chemotherapy-induced agranulocytosis detected by a prospective pharmacovigilance program in a tertiary hospital. Basic Clin Pharmacol Toxicol. 2015;117(6):399\u2013408.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"11","key":"873_CR12","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00228-004-0836-y","volume":"60","author":"L Ib\u00e1\u00f1ez","year":"2005","unstructured":"Ib\u00e1\u00f1ez L, Vidal X, Ballar\u00edn E, et al. Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol. 2005;60(11):821\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"873_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00228-002-0465-2","volume":"58","author":"K Hedenmalm","year":"2002","unstructured":"Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol. 2002;58(4):265\u201374.","journal-title":"Eur J Clin Pharmacol"},{"key":"873_CR14","unstructured":"Spanish Medicines and Medical Devices Agency (AEMPS). Ministry of Health, Consumption and Social Welfare of Spain. Metamizol y riesgo de agranulocitosis [Metamizol and risk of agranulocytosis]. 2018 Oct 30 [cited 2018 Dec 28]. https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2018\/NI_MUH_FV-15-2018-metamizol-agranulocitosis.htm ."},{"issue":"5","key":"873_CR15","first-page":"200","volume":"110","author":"E Andr\u00e8s","year":"2017","unstructured":"Andr\u00e8s E, Mourot-Cottet R, Maloisel F, et al. Idiosyncratic drug-induced neutropenia and agranulocytosis. QJM. 2017;110(5):200\u2013305.","journal-title":"QJM"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-019-00873-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-019-00873-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-019-00873-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T11:34:19Z","timestamp":1663846459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-019-00873-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,29]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["873"],"URL":"https:\/\/doi.org\/10.1007\/s11096-019-00873-9","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2019,6,29]]},"assertion":[{"value":"28 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}